Within the Oral Delivery Vaccines market taxonomy, the Types dimension classifies products into five principal formats: Live attenuated, Inactivated, Subunit, DNA/RNA, and Recombinant vector vaccines. Live attenuated oral vaccines retain replication competence, enabling mucosal immunity but requiring stringent safety controls; they command a premium price and occupy a niche in rotavirus and polio programs. Inactivated vaccines, comprising killed pathogens, provide a safer profile for immunocompromised populations, contributing modestly to market volume due to higher manufacturing costs. Subunit vaccines deliver purified antigens, offering targeted immune responses and facilitating rapid scale‑up, thus representing a growing share as platform technologies mature. DNA/RNA oral vaccines, still emerging, leverage nucleic‑acid delivery for rapid antigen expression, promising high scalability though currently limited by stability challenges. Recombinant vector vaccines employ engineered microorganisms (e.g., adenovirus, Salmonella) to present antigens, balancing immunogenicity with manufacturing complexity. Each type’s share is determined by disease indication, regulatory pathway, and cost structure, collectively shaping the market’s revenue composition.
